Actionable trade ideas with defined risk and time horizons.
Curated trade ideas across equities, options, and other instruments, featuring clear directional bias, time horizon, and risk considerations. Trade ideas are designed to align market context, technical structure, and risk management principles.
1,065 total articles
Slide Insurance (SLDE) has been pummeled by research reports and law-firm probes, but fundamentals and a $75M buyback argue for a tactical long. Technicals are neutral and short interest is meaningful — set a disciplined entry, stop and target for a mid-term trade.
USA Rare Earth just got a headline-making financing package from Washington that materially reduces bankruptcy risk and funds an aggressive build-out. That same government relationship is the source of rapid sentiment swings after reports the administration may scale back price-floor support. For nimble traders, there is a defined mid-term long tra…
Alphabet looks set to resolve a year-long re-rating debate. With strong AI adoption across Search, YouTube and Google Cloud, healthy free cash flow, and a manageable capital structure, this trade buys a controlled exposure to upside while capping downside risk around structural moving averages.
Village Farms (VFF) has moved from stabilization to expansion. With EU-GMP exports surging, a planned capacity conversion in B.C., and solid free cash flow, the stock looks positioned for a multi-month recovery. This trade idea lays out an entry, stop, targets, catalysts and the risks to watch.
Palantir ($PLTR) looks set for a high-volatility move around the 02/02/2026 earnings print. The company’s commercial momentum and rising free cash flow underpin a tactical long trade from current levels. Valuation remains extreme, so this is a trade with a tight stop and a mid-term horizon designed to capture a rebound while preserving capital.
Berkshire Hathaway is trading below its 50-day and 20-day averages on weak momentum, but the underlying fundamentals remain robust: $1.04T market cap, P/E ~15.4, free cash flow of $19.3B and a low debt load. This trade targets a reversion to the 52-week high while keeping risk tight below recent lows.
Carlisle Companies (CSL) is a high-quality operator in roofing, insulation and waterproofing that combines durable free cash flow, a disciplined capital return program, and structural demand drivers (energy codes, severe-weather resilience) to offer a defensively biased growth trade. Valuation is reasonable relative to cash generation: market cap ~…
Supernus is a mid-cap CNS specialist with a stabilizing cash flow profile, an active pipeline (SPN-817) and a strategic acquisition of Sage Therapeutics. The balance sheet and free cash flow generation support valuation upside from current levels. We recommend a buy with specific entry, stop and target for a 180-trading-day horizon.
Envela (ELA) is a small-cap recycler and re-commerce operator whose exposure to secondary-market bullion and reclaimed precious metals gives it direct leverage to rising gold. The stock trades near $13.64 after a pullback; with a market cap around $353M, modest leverage, positive free cash flow and a tight float, a renewed gold rally and improving …
BioMarin (BMRN) offers a measurable risk-reward as a mid-term swing trade. Entry at the current price captures near-term upside from Amicus integration, steady free cash flow, and a valuation that still looks reasonable versus growth prospects. We lay out an actionable plan with a $72 target and a $51.50 stop over a 45-trading-day horizon.
Duolingo is down sharply from its 2025 highs but still generates strong free cash flow, has low leverage and high returns on capital. Technicals show oversold conditions and elevated short interest that can fuel a squeeze. This trade idea outlines an actionable entry at $134.08, a $210 target over the next 180 trading days, and a $110 stop — with c…
Dassault Systèmes (DASTY) offers a compelling long trade: attractive exposure to industrial digitalization and emerging markets like materials informatics and in‑silico trials, a reasonable valuation at a $36.9B market cap and upside to $38 if execution and adoption accelerate. Set a disciplined stop at $24.50 and plan for a long term (180 trading …
Evolution AB (EVVTY) is trading near its 52-week low despite a strong franchise in live casino solutions, a healthy dividend yield and a P/E of ~10.7. Technicals show downside pressure but also oversold momentum. This trade idea argues for a long position sized as risk-tolerant exposure: entry $65.00, target $85.00, stop $60.00, long-term horizon (…
Western Union (WU) trades at bargain multiples — roughly 5x earnings and ~5x EV/EBITDA — while yielding north of 10%. Immigration policy risk and fintech competition create tangible downside, but the stock's valuation, recurring free cash flow, and catalysts (Solana stablecoin, digital services growth, possible buybacks) make a mid-term long trade …
Apple reported a blowout fiscal Q1 with $143.8B revenue and $85.3B in iPhone sales. With peers repriced on AI froth and memory-price uncertainty, Apple looks like a lower-beta way to capture tech upside. We upgrade to a buy and lay out an actionable mid-term trade: entry $259.49, stop $248.00, target $288.00 (45 trading days).
A heavy Jan selloff has pushed AppLovin (APP) into oversold territory despite 68% revenue growth and $3.35B in free cash flow. Headlines about Alphabet's Project Genie are acting as a convenient scapegoat for the software rout; the fundamentals and cash generation argue for a mid-term long trade with defined risk controls.
Brown-Forman (BF.B) has been punished by cyclical demand and regional headwinds, but the business remains cash generative, carries manageable leverage, and trades at reasonable multiples. This trade idea outlines a long-term buy with specific entry, stop, and target levels and frames the risks and catalysts that will determine whether this setup pa…
Regeneron looks attractively valued for a 2026 re-acceleration. After a mixed quarter where Eylea faced pressure but company-level revenues and cash flow held up, the stock trades at ~17-18x forward earnings with strong free cash flow. Upcoming pipeline readouts, label expansions, and a material manufacturing buildout create a plausible path to dou…
Starbucks is showing early signs of a meaningful operational reset: comparable-store sales accelerated to +4% and U.S. transactions turned positive for the first time in eight quarters. Valuation is rich by historical earnings multiples, but the company still generates meaningful free cash flow and yields 2.66% in dividends. This trade targets a mi…
S&P Global is positioned to capture outsized value as it standardizes private-market data and completes the Mobility spin-off in 2026. The company generates strong free cash flow, maintains a conservative balance sheet, and just raised the dividend modestly while preparing to separate Mobility. That combination argues for a re-rating over the next …
Amerant (AMTB) offers a risk/reward that looks attractive if CRE stress continues to stabilize. The franchise trades at roughly $21.72 with a market cap under $1.0B, P/E ~13x and P/B below 1.0. We propose a long trade sized for a mid-to-long holding period, with a clear entry, stop and target tied to a re-rating and improving fundamentals.
iRhythm's recent selloff over a delayed product launch created a buying opportunity. With 2026 guidance of $870-880M (17-18% growth), positive free cash flow, $1.74B of cash on the balance sheet and an EV/sales multiple in the mid-single digits, the risk/reward favors a long trade sized for a volatility-aware portfolio. This idea lays out an entry,…
ProKidney's autologous renal cell therapy, rilparencel, showed statistically significant Phase 2 improvements in eGFR slope and an encouraging safety profile. With a market capitalization near $280M, an EV of roughly $185M and active short interest, the stock offers an asymmetric risk/reward to disciplined traders. This trade idea lays out an entry…
Benitec Biopharma’s BB-301 program just cleared two practical hurdles: convincing early efficacy/durability in Oculopharyngeal Muscular Dystrophy (OPMD) and a $100 million financing that materially derisks development funding. Given the clinical readouts (including 24-month durability in patient 1) and an EV of roughly $318M, a long trade with defi…
Kirby (KEX) trades at a mid-teens to low-twenties multiple on current earnings and offers solid free cash flow and an active buyback program. That makes the valuation interesting for a tactical long, but recent weakness in momentum indicators and lingering macro risks argue for a disciplined entry, a clear stop, and a mid-term horizon to let fundam…
